A detailed history of Rhumbline Advisers transactions in Verona Pharma PLC stock. As of the latest transaction made, Rhumbline Advisers holds 958 shares of VRNA stock, worth $43,148. This represents 0.0% of its overall portfolio holdings.

Number of Shares
958
Previous 841 13.91%
Holding current value
$43,148
Previous $12,000 125.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$15.46 - $30.16 $1,808 - $3,528
117 Added 13.91%
958 $27,000
Q2 2024

Aug 01, 2024

BUY
$11.48 - $17.02 $3,937 - $5,837
343 Added 68.88%
841 $12,000
Q1 2024

May 09, 2024

BUY
$15.3 - $20.24 $3,381 - $4,473
221 Added 79.78%
498 $8,000
Q4 2023

Feb 08, 2024

BUY
$11.94 - $20.47 $943 - $1,617
79 Added 39.9%
277 $5,000
Q3 2023

Nov 09, 2023

BUY
$16.3 - $22.09 $733 - $994
45 Added 29.41%
198 $3,000
Q2 2023

Aug 08, 2023

BUY
$19.41 - $23.43 $2,969 - $3,584
153 New
153 $3,000

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.75B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.